Cerebrospinal fluid (CSF) CXCL13 was shown to correlate with markers of intrathecal inflammation and CSF oligoclonal IgM bands (IgMOB) have been associated with a more severe Multiple Sclerosis (MS) course. We correlated CSF CXCL13 levels with clinical, MRI and CSF parameters, including CSF IgMOB, in 110 Clinically Isolated Syndrome (CIS) patients. CSF CXCL13 levels correlated with CSF cell count, total protein, IgG Index and with the presence of CSF IgGOB and IgMOB. CSF CXCL13 levels ≥15.4 pg/ml showed a good positive predictive value and specificity for a MS diagnosis and for a clinical relapse within one year from onset.
In MS patients, elevated CSF CXCL13 levels correlated with CSF cell count, IgG index, presence of oligoclonal IgG bands (IgGOB), number of MRI brain lesions and presence of MRI gadolinium-enhancing lesions (Krumbholz et al., 2006; Kuenz et al., 2008; Festa et al., 2009; Sellebjerg et al., 2009; Khademi et al., 2011; Ragheb et al., 2011; Senel et al., 2014) . Furthermore, they were associated with a higher relapse rate and to a higher risk of conversion to MS in Clinically Isolated Syndrome (CIS) patients (Brettschneider et al., 2010; Khademi et al., 2011) .
In addition, CSF CXCL13 levels correlated with the number of CSF CD5+ B cells and with intrathecal IgM production (Villar et al., 2010) . Intrathecal IgM synthesis (Villar et al., 2002 (Villar et al., , 2003 Mandrioli et al., 2008; Sola et al., 2011) , and intrathecal lipid-specific IgM synthesis (Villar et al., 2005; Thangarajh et al., 2008) have been associated with a more aggressive disease course and with an earlier conversion to Clinically Definite MS (CDMS) in CIS patients (Boscá et al., 2010; Ferraro et al., 2013) .
Our aim was to correlate CSF CXCL13 levels with clinical, MRI and CSF parameters, including CSF oligoclonal IgM bands (IgMOB), in a cohort of CIS patients who were followed up for at least two years or until a relapse occurred, and to explore the possible role of CXCL13 in predicting a MS/CDMS diagnosis and an "early" MS/CDMS diagnosis, defined as a diagnosis or a relapse occurring within one year from onset.
